GVAX is portfolio of irradiated tumor cell lines that
have been engineered to recruit immune cells by expressing GM-CSF, the most
potent immune cell recruitment factor. GVAX vaccines
are well suited for combination therapy because (a) they present numerous
antigens to the immune system, thereby enabling a broad-based immune response
and (b) have a well-established, favorable safety profile demonstrated in multiple clinical trials.
The combination of
GVAX Pancreas and the immune checkpoint inhibitor
ipilimumab (Yervoy® from Bristol-Myers Squibb) was more effective than
ipilimumab alone in a 30 patient study: mOS was 3.6 vs. 5.7 months
(p=0.072; HR=0.51) (J Immunother. 36(7), 382-389). In a study of
GVAX Prostate and ipilimumab in 28 patients with metastatic
castration-resistant prostate cancer, 50% or greater declines in
prostate-specific antigen (PSA) were seen from baseline in seven
patients (25%) (Lancet Oncol. 13(5), 509-517).
In addition, Aduro has demonstrated
that co-formulation of CDNs with GVAX, termed STINGVAX, results in superior anti-tumor efficacy in pre-clinical cancer models compared to GVAX alone.